Supplement, Optimal Timing of Stage 2

Slides:



Advertisements
Similar presentations
Supplemental Figure 1 A No. at risk T T T
Advertisements

Justus-Liebig-University
HOW I DO IT ? MODIFIED NORWOOD’S OPERATION
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
Leapfrog’s “Survival Predictor”: Composite Measures for Predicting Hospital Surgical Mortality May 7, 2008.
Palliative RVOT procedures
Meredith Cook – PharmD Candidate Mercer University COPHS August, 2012 Cognitive Trajectories after Postoperative Delirium.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
95th Annual Meeting: American Association for Thoracic Surgery
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Division of Cardiology Department of Internal Medicine Tae Kyung Yu
1 Sex and H-Hope Intervention Effects on Patterns of Weight Gain during Hospital Stay for Premature Infants Rosemary White-Traut, PhD, RN, FAAN Kristin.
J Am Coll Cardiol. Published online September 28, doi: /j.jacc
Society of Thoracic Surgeons 53rd Annual Meeting
Ebstein Anomaly Cohort: Update
CHSS Fall Work Weekend November 18, 2016
Risk Factors Preeclampsia in previous pregnancies
Navigator Supported Triage in Acute Medicine
Feeding Productive Ewes
The Optimal Timing of Stage-2-Palliation after the Norwood Operation: A Multi-Institutional Analysis from the CHSS CHSS Fall Work Weekend November 19,
Natural History of Tricuspid Regurgitation: Primary vs Secondary
TAVR Requirements for the Cath Lab
Pirooz Eghtesady and Tara Karamlou, and Members of the Working Group
MedStar Washington Hospital Center Cardiac Catheterization Conference
Is There a Need to Address AF in patients Undergoing Valve Surgery?
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Larissa Registry on CAS and CEA:
TAVI „Catch me if you can!“
Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,
Insights from the NCDR® STS/ACC TVT Registry.
Fig. 1 Log-rank test comparing survival in patients undergoing surgical repair with those treated with TEVAR. Black line: TEVAR; grey line: surgical repair.
Homograft Replacement of the aortic valve:Ten-year results
Mohamed Eid Fawzy, FRCP, FACC, FESC October 6 University Cairo, EGYPT
Annual Outcomes With Transcatheter Valve Therapy
Supplement on Multiple Regression Interpretation
Recently Diagnosed vs Chronic HF Associated with Better Outcomes
Annual Outcomes With Transcatheter Valve Therapy
Etiology of Acute Kidney Injury in Neonates
In Search of the Ideal Pulmonary Blood Source for the Norwood Procedure: A Meta- Analysis and Systematic Review  Vikas Sharma, MBBS, Salil V. Deo, MBBS,
The impact of a dedicated single-ventricle home-monitoring program on interstage somatic growth, interstage attrition, and 1-year survival  Christopher.
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )
Work Weekend, Toronto November 18-20, 2016
Ross operation: 16-year experience
Can I color yellow?. Can I color yellow?
Mortality Data From the BASKET LATE Trial and PREMIER Registry
Eric M. Graham, MD, Sinai C. Zyblewski, MD, Jacob W
The Optimal Timing of Stage-2-Palliation After the Norwood Operation
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Surgical management of competing pulmonary blood flow affects survival before Fontan/Kreutzer completion in patients with tricuspid atresia type I  Travis.
Volume 155, Issue 5, Pages e3 (November 2018)
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Supplemental Figure 1A Pt Pt Pre-treatment
Travis J. Wilder, MD, Brian W. McCrindle, MD, Edward J
The Patient’s Voice: Valve Replacement for Bicuspid Aortic Valve
Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions: Risk factors and their interaction with shunt type 
Biventricular strategies for neonatal critical aortic stenosis: High mortality associated with early reintervention  Edward J. Hickey, MD, Christopher.
Jason R. Buckley, MD, Venu Amula, MD, Peter Sassalos, MD, John M
André Rüffer, MD, Florian Arndt, MD, Sergej Potapov, MS, Thomas S
Volume 76, Issue 3, Pages (August 2009)
Is age a predictor of mortality in a UK medical high dependency unit?
Older children at the time of the Norwood operation have ongoing mortality vulnerability that continues after cavopulmonary connection  Bahaaldin Alsoufi,
The Ross procedure: Outcomes at 20 years
Baseline characteristics of study population
Prosthesis–patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: Effect on survival,
Survival of End Stage Renal Failure Patients with Cancer
Summary of the aortic valve procedures performed in the initial BAV group (A) and the initial SAV group (B), by order of reinterventions (first on the.
Nicholas D. Fletcher, MD¹ Charles E. Johnston III, MD²
Presentation transcript:

Supplement, Optimal Timing of Stage 2 CHSS Fall Work Weekend Jim Meza

% Months since Norwood Poor candidate for Stage 2 7 months 4.8 months  Risk Factor for Death Value After Norwood Birth weight (kg) 2.5 kg MBTS vs. RVPA conduit MBTS Smaller TV diameter (cm) on baseline echo, indexed to BSA 6.92 Aortic valve atresia on baseline echo No After S2P RV dysfunction on pre-S2P echo, moderate or severe Yes Younger age at S2P (days), natural log transformation N/A Weight-for-age z-score on pre-S2P cardiac catheterization -2.1 Required MCS post-Norwood 7 months 4.8 months % 3.5 months 2 months Months since Norwood

% Months since Norwood Poor candidate for Stage 2 Blue, purple = RVPA conduit Green, orange = MBTS  Risk Factor for Death Value After Norwood Birth weight (kg) 2.5 kg MBTS vs. RVPA conduit Smaller TV diameter (cm) on baseline echo, indexed to BSA 6.92 Aortic valve atresia on baseline echo No After S2P RV dysfunction on pre-S2P echo, moderate or severe Yes Younger age at S2P (days), natural log transformation Weight-for-age z-score on pre-S2P cardiac catheterization -2.1 Required MCS post-Norwood RVPA MBTS 7 months 4.8 months 7 months % 4.8 months 3.5 months 3.5 months I would interpret that as – if you are a poor candidate for stage 2 and require intervention at an early age – shunt type does not matter and the survival cost will be very high 2 months 2 months Months since Norwood

% Months since Norwood Patient with more RF for death after Norwood  Risk Factor for Death Value After Norwood Birth weight (kg) 2.8 kg MBTS vs. RVPA conduit MBTS Smaller TV diameter (cm) on baseline echo, indexed to BSA 6.08 Aortic valve atresia on baseline echo Yes After S2P RV dysfunction on pre-S2P echo, moderate or severe No Younger age at S2P (days), natural log transformation N/A Weight-for-age z-score on pre-S2P cardiac catheterization -1.8 Required MCS post-Norwood 2.5 months 2 months % 5.3 months 7 months This figure was for our patient with characteristics that place them at higher risk for death after the Norwood operation (MTS, lower birthweight, +AA). S2P appears it may rescue these patients. Compare with previous slide, who is a poor candidate for CPS, with RV dysfunction and a lower weight for age z-score, who takes a bigger hit for mortality based on younger age at stage 2, and who appars to have a much greater risk for perioperative mortality, especially when younger at tiem of stage 2. Months since Norwood

% Months since Norwood Patient with more RF for death after Norwood Blue, purple = RVPA conduit Green, orange = MBTS  Risk Factor for Death Value After Norwood Birth weight (kg) 2.8 kg MBTS vs. RVPA conduit Smaller TV diameter (cm) on baseline echo, indexed to BSA 6.08 Aortic valve atresia on baseline echo Yes After S2P RV dysfunction on pre-S2P echo, moderate or severe No Younger age at S2P (days), natural log transformation N/A Weight-for-age z-score on pre-S2P cardiac catheterization -1.8 Required MCS post-Norwood RVPA 5.3 months 2.5 months MBTS 7 months 2.5 months % 5.3 months 7 months Months since Norwood